Abstract

Background

Circadian patterns of migraine attacks have been reported by patients but remain understudied. In animal models, circadian phases are generally not taken into consideration. In particular, rodents are nocturnal animals, yet they are most often tested during their inactive phase during the day. This study aims to test the validity of CGRP-induced behavioral changes in mice by comparing responses during the active and inactive phases.

Methods

Male and female mice of the outbred CD1 strain were administered vehicle (PBS) or CGRP (0.1 mg/kg, i.p.) to induce migraine-like symptoms. Animals were tested for activity (homecage movement and voluntary wheel running), light aversive behavior, and spontaneous pain at different times of the day and night.

Results

Peripheral administration of CGRP decreased the activity of mice during the first hour after administration, induced light aversive behavior, and spontaneous pain during that same period of time. Both phenotypes were observed no matter what time of the day or night they were assessed.

Conclusions

A decrease in wheel activity is an additional clinically relevant phenotype observed in this model, which is reminiscent of the reduction in normal physical activity observed in migraine patients. The ability of peripheral CGRP to induce migraine-like symptoms in mice is independent of the phase of the circadian cycle. Therefore, preclinical assessment of migraine-like phenotypes can likely be done during the more convenient inactive phase of mice.

Details

Title
CGRP induces migraine-like symptoms in mice during both the active and inactive phases
Author
Wattiez Anne-Sophie 1   VIAFID ORCID Logo  ; Gaul, Olivia J 2 ; Adisa, Kuburas 2 ; Zorrilla, Erik 3 ; Waite, Jayme S 2 ; Mason, Bianca N 4 ; Castonguay, William C 2 ; Wang Mengya 5 ; Robertson, Bennett R 2 ; Russo, Andrew F 6 

 University of Iowa, Department of Molecular Physiology and Biophysics, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294); Veterans Administration Health Center, Center for the Prevention and Treatment of Visual Loss, Iowa City, USA (GRID:grid.214572.7) 
 University of Iowa, Department of Molecular Physiology and Biophysics, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294) 
 University of Iowa, Neuroscience Program, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294) 
 University of Iowa, Department of Molecular Physiology and Biophysics, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294); University of Texas at Dallas, Present address: Brain and Behavior Sciences, Center for Advanced Pain Studies, Richardson, USA (GRID:grid.267323.1) (ISNI:0000 0001 2151 7939) 
 University of Iowa, Department of Pharmacology, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294) 
 University of Iowa, Department of Molecular Physiology and Biophysics, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294); Veterans Administration Health Center, Center for the Prevention and Treatment of Visual Loss, Iowa City, USA (GRID:grid.214572.7); University of Iowa, Department of Neurology, Iowa City, USA (GRID:grid.214572.7) (ISNI:0000 0004 1936 8294) 
Publication year
2021
Publication date
Dec 2021
Publisher
Springer Nature B.V.
ISSN
11292369
e-ISSN
11292377
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2546784933
Copyright
© The Author(s) 2021. corrected publication 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.